UY37980A - Compuestos novedosos para tratar enfermedades parasitarias - Google Patents

Compuestos novedosos para tratar enfermedades parasitarias

Info

Publication number
UY37980A
UY37980A UY0001037980A UY37980A UY37980A UY 37980 A UY37980 A UY 37980A UY 0001037980 A UY0001037980 A UY 0001037980A UY 37980 A UY37980 A UY 37980A UY 37980 A UY37980 A UY 37980A
Authority
UY
Uruguay
Prior art keywords
compounds
novelty
parasitic diseases
treat parasitic
treat
Prior art date
Application number
UY0001037980A
Other languages
English (en)
Inventor
Tsutomu Akama
Jason S Halladay
Robert T Jacobs
Yang Liu
Jacob J Plattner
Yong-Kang Zhang
David Scott Carter
Michael John Witty
Original Assignee
Anacor Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anacor Pharmaceuticals Inc filed Critical Anacor Pharmaceuticals Inc
Publication of UY37980A publication Critical patent/UY37980A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/027Organoboranes and organoborohydrides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • A61K31/43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/10Anthelmintics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/14Ectoparasiticides, e.g. scabicides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención proporciona determinados compuestos de ésteres de oxaborol y composiciones de estos, los cuales son útiles para tratar enfermedades asociadas con parásitos, tales como tripanosomiasis animal africana.
UY0001037980A 2016-05-12 2018-11-22 Compuestos novedosos para tratar enfermedades parasitarias UY37980A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662335565P 2016-05-12 2016-05-12

Publications (1)

Publication Number Publication Date
UY37980A true UY37980A (es) 2020-06-30

Family

ID=58699201

Family Applications (2)

Application Number Title Priority Date Filing Date
UY0001037236A UY37236A (es) 2016-05-12 2017-05-10 Ésteres de oxaborol y sus usos
UY0001037980A UY37980A (es) 2016-05-12 2018-11-22 Compuestos novedosos para tratar enfermedades parasitarias

Family Applications Before (1)

Application Number Title Priority Date Filing Date
UY0001037236A UY37236A (es) 2016-05-12 2017-05-10 Ésteres de oxaborol y sus usos

Country Status (31)

Country Link
US (4) US10562921B2 (es)
EP (2) EP3578562B1 (es)
JP (2) JP6715957B2 (es)
KR (2) KR102231489B1 (es)
CN (2) CN109153688A (es)
AR (2) AR108450A1 (es)
AU (2) AU2017263785B2 (es)
BR (2) BR122023022427A2 (es)
CA (1) CA3023490C (es)
CL (2) CL2018003187A1 (es)
CO (1) CO2018012077A2 (es)
CR (2) CR20180502A (es)
DK (1) DK3578562T3 (es)
EA (2) EA034415B1 (es)
EC (2) ECSP18091065A (es)
ES (1) ES2882782T3 (es)
HK (1) HK1258717A1 (es)
HU (1) HUE056320T2 (es)
IL (2) IL262453A (es)
MA (1) MA44968A (es)
MX (2) MX2018013743A (es)
NI (2) NI201801171A (es)
NZ (1) NZ746906A (es)
PE (2) PE20190119A1 (es)
PT (1) PT3578562T (es)
SG (1) SG11201809237RA (es)
TN (2) TN2019000106A1 (es)
TW (1) TWI629279B (es)
UA (2) UA120999C2 (es)
UY (2) UY37236A (es)
WO (1) WO2017195069A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10070649B2 (en) 2013-01-30 2018-09-11 Agrofresh Inc. Volatile applications against pathogens
US11039617B2 (en) 2013-01-30 2021-06-22 Agrofresh Inc. Large scale methods of uniformly coating packaging surfaces with a volatile antimicrobial to preserve food freshness
EP3426029B1 (en) 2016-03-07 2023-08-30 AgroFresh Inc. Synergistic methods of using benzoxaborole compounds and preservative gases as an antimicrobial for crops
ES2882782T3 (es) * 2016-05-12 2021-12-02 Anacor Pharmaceuticals Inc Derivados de benzoxaborol amida L-valinato para el tratamiento de enfermedades parasitarias
BR112020010927A2 (pt) * 2017-11-30 2020-12-01 Boragen, Inc. compostos de benzoxaborol e formulações dos mesmos
JP2020180170A (ja) * 2019-04-23 2020-11-05 東ソー株式会社 ハロゲン含有ポリエーテルポリオール組成物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
DK0495421T3 (da) 1991-01-15 1996-12-09 Alcon Lab Inc Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
GB9411587D0 (en) 1994-06-09 1994-08-03 Zeneca Ltd Compound, composition and use
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
JO3396B1 (ar) 2007-06-20 2019-10-20 Anacor Pharmaceuticals Inc جزيئات صغيرة تحتوي على البورون
WO2010045505A1 (en) * 2008-10-15 2010-04-22 Anacor Pharmaceuticals, Inc Boron-containing small molecules as anti-protozoal agents
US9493489B2 (en) * 2008-10-15 2016-11-15 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-protozoal agents
WO2011019618A1 (en) 2009-08-14 2011-02-17 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
US8933018B2 (en) 2011-02-07 2015-01-13 Rempex Pharmaceuticals, Inc. Boron containing polybasic bacterial efflux pump inhibitors and therapeutic uses thereof
AU2012320382B2 (en) * 2011-10-07 2015-11-26 Syngenta Participations Ag Method for protecting useful plants or plant propagation material
AR088669A1 (es) 2011-11-21 2014-06-25 Lilly Co Eli Derivados de dihidrodibenzo[c][1,2]oxaborol y dihidroisoxazol utiles para el control de ectoparasitos
US8669207B1 (en) 2013-01-30 2014-03-11 Dow Agrosciences, Llc. Compounds and compositions
US9493490B1 (en) 2013-07-22 2016-11-15 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
LT3030519T (lt) 2013-08-09 2022-04-11 Glaxosmithkline Intellectual Property (No. 2) Limited Tricikliniai benzoksaborolo junginiai ir jų naudojimas
WO2015097276A1 (en) * 2013-12-23 2015-07-02 Syngenta Participations Ag Benzoxaborole fungicides
EP3337809A1 (en) * 2015-08-17 2018-06-27 Syngenta Participations Ag 1-hydroxy-3h-2,1-benzoxaborole derivatives and their use as microbiocides
ES2882782T3 (es) * 2016-05-12 2021-12-02 Anacor Pharmaceuticals Inc Derivados de benzoxaborol amida L-valinato para el tratamiento de enfermedades parasitarias

Also Published As

Publication number Publication date
JP6715966B2 (ja) 2020-07-01
KR102243775B1 (ko) 2021-04-22
TW201808968A (zh) 2018-03-16
UA121354C2 (uk) 2020-05-12
US10562921B2 (en) 2020-02-18
CA3023490C (en) 2021-06-08
NZ746906A (en) 2020-06-26
IL263161B (en) 2022-05-01
AU2017263785A1 (en) 2018-10-25
JP6715957B2 (ja) 2020-07-01
UY37236A (es) 2018-01-02
US20230132298A1 (en) 2023-04-27
EP3455227A1 (en) 2019-03-20
CN109153688A (zh) 2019-01-04
AR113543A2 (es) 2020-05-13
CR20180502A (es) 2018-12-21
ECSP18091065A (es) 2019-07-31
CL2018003187A1 (es) 2019-01-11
DK3578562T3 (da) 2021-07-12
IL263161A (en) 2018-12-31
ECSP19026702A (es) 2019-06-30
JP2019081770A (ja) 2019-05-30
WO2017195069A1 (en) 2017-11-16
TWI629279B (zh) 2018-07-11
CR20180560A (es) 2019-01-25
HK1258717A1 (zh) 2019-11-15
EA201892475A1 (ru) 2019-04-30
ES2882782T3 (es) 2021-12-02
EP3578562A1 (en) 2019-12-11
IL262453A (en) 2018-12-31
MA44968A (fr) 2019-03-20
NI201801172A (es) 2019-04-10
US20210101916A1 (en) 2021-04-08
US11578087B2 (en) 2023-02-14
SG11201809237RA (en) 2018-11-29
CA3023490A1 (en) 2017-11-16
NI201801171A (es) 2019-04-10
HUE056320T2 (hu) 2022-02-28
AU2017263785B2 (en) 2019-10-03
EA034415B1 (ru) 2020-02-05
CN109503637B (zh) 2021-03-16
CN109503637A (zh) 2019-03-22
KR102231489B1 (ko) 2021-03-23
CL2018003377A1 (es) 2019-01-11
KR20190005982A (ko) 2019-01-16
EP3578562B1 (en) 2021-06-23
BR122023022427A2 (pt) 2023-12-26
EA201892203A1 (ru) 2019-04-30
UA120999C2 (uk) 2020-03-10
BR122018076188A2 (pt) 2019-09-10
US20170327519A1 (en) 2017-11-16
AU2018264116A1 (en) 2018-12-06
BR112018071931A2 (pt) 2019-02-05
JP2019520326A (ja) 2019-07-18
US20200017531A1 (en) 2020-01-16
US10882872B2 (en) 2021-01-05
EA036661B1 (ru) 2020-12-04
PE20190119A1 (es) 2019-01-17
AU2018264116B2 (en) 2020-03-12
MX2018013743A (es) 2019-05-02
MX2018015410A (es) 2019-05-27
PE20191077A1 (es) 2019-08-20
KR20190002695A (ko) 2019-01-08
PT3578562T (pt) 2021-08-05
TN2019000106A1 (en) 2020-10-05
AR108450A1 (es) 2018-08-22
TN2018000351A1 (en) 2020-06-15
CO2018012077A2 (es) 2018-11-22

Similar Documents

Publication Publication Date Title
UY37134A (es) Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4
UY37980A (es) Compuestos novedosos para tratar enfermedades parasitarias
CL2017001459A1 (es) Biarilo compuestos útiles para el tratamiento de enfermedades humanas en oncología, neurología e inmunología
CL2019002304A1 (es) Compuestos para el tratamiento del cáncer.
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
ECSP17073191A (es) Compuestos heterocíclicos como inhibidores de lsd1
CO2017011484A2 (es) Inhibidores de bromodominio
PE20180243A1 (es) Composiciones que comprenden cepas bacterianas
ECSP16073190A (es) Ciclopropilaminas como inhibidores de lsd1
DOP2016000295A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
EA201890052A1 (ru) Регуляторы nrf2
UY37018A (es) Inhibidores bicíclicos de pad4
UY36705A (es) Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj
CL2019003419A1 (es) Polipéptidos que antagonizan la señalización wnt en células tumorales.
GT201800020A (es) Inhibidores del receptor del factor estimulador de colonias 1 (csf-1r)
DOP2017000120A (es) 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139
CL2018000597A1 (es) Métodos para tratar enfermedades inflamatorias
UY37017A (es) Inhibidores aza-bencimidazol de pad4
UY36080A (es) Compuestos inhibidores de metaloenzima como fungicidas.
UY36081A (es) Compuestos inhibidores de metaloenzima como fungicidas.
ECSP16074207A (es) Pirazinas moduladoras de gpr6
BR112018068798A2 (pt) composições e métodos para tratamento de doenças parasíticas